These four simple words say everything about who we are and what we believe in. We don’t see medicines as just molecules, but as a means to help patients regain their health.
We consider it our duty to ensure good health can be delivered to those who need it, and to promote wellness among them. To do this, we try to create better healthcare solutions, and then act with speed to make much-needed medicines accessible to patients around the world.
Create value for our stakeholders, but respect our natural environment. Keep at heart the best interests of the communities in which we live and work.
Uphold the highest standards of integrity and transparency in all our conversations.
Continuously improve our infrastructure, work practices and behaviours to make our environment the safest place to work.
Design our products and processes to be superior in quality. It is the surest way to delight our stakeholders.
Use the expertise and resources from across our global network to create better value for our stakeholders.
Strive to achieve more with less. Innovate and improve consistently and always focus on ways to eliminate waste.
Stay committed to creating a work environment that encourages diverse perspectives and upholds the dignity of work and individuals.
Our Management Council ensures everything we do aligns with our purpose of addressing patient needs and business goals. The Council decides on our company’s long-term strategy, growth initiatives and overall organisational health. They play an important role in ensuring safe and productive operations, as well as controlling risks in the business.
Scientist, philanthropist and entrepreneur Dr. K Anji Reddy’s passion for drug discovery and pioneering contributions to making medicines affordable are legendary. Born in Tadepalli in the Guntur district of Andhra Pradesh, India, in a well-to-do farming family, he grew up watching his father make herbal pills and distribute them for free.
The seed of Dr. Anji Reddy’s lifelong passion for pharmaceuticals was sown as he pursued a BSc Tech degree at the University Department of Chemical Technology, Mumbai. He went on to secure a doctorate in Chemical Engineering from the National Chemical Laboratory, Pune, and worked for six years at the state-owned Indian Drugs and Pharmaceuticals Ltd. Here, his entrepreneurial ambitions were fired up; in 1973, he left IDPL and cofounded two bulk drug manufacturing ventures over the next ten years.
In 1984, Dr. Anji Reddy decided to strike out on his own and established Dr. Reddy’s Laboratories. He also acquired Cheminor Drugs, a bulk drug manufacturing company.
From the outset, Dr. Anji Reddy realised that if medicines had to serve their purpose, they had to be affordable and accessible. In as early as 1973, he had penned his vision: “To bring new molecules into the country at a price the common man can afford.”
Even as he built a global conglomerate, Dr. Anji Reddy ensured that he shared his success with those less fortunate. He did not see his pharmaceutical business as being very different from the social enterprises he founded. For example, he set up the Livelihood Advancement Business School to help young people from disadvantaged backgrounds to upskill, secure employment and become contributing members of society.
Until the end, Dr. Anji Reddy remained true to his passion for drug discovery, to the extent of setting up a separate company using his own funds. It was not only the compulsion of innovation that drove him, but also his conviction that medicines must be affordable. He referred to this as his “unfinished agenda”.
Dr. K Anji Reddy established Dr. Reddy’s Laboratories, and we commenced operations at our first facility in Jeedimetla.
The company went public and was listed on the Bombay Stock Exchange. We also entered the international market during this year with the export of the API Methyldopa.
We received our first USFDA approval for the API Ibuprofen.
We became the first Indian pharmaceutical company to export APIs for Norfloxacin and Ciprofloxacin to Europe and the Far East.
Dr. Reddy’s started manufacturing Omeprazole, which continues to be one of the company’s best-known products worldwide.
The company entered Russia, then the single-largest international market.
The Dr. Reddy’s Research Foundation was established to run drug discovery programmes focused on diabetes and cancer. We were also among the first Indian companies to commission drug discovery programmes for metabolic disorders, inflammation and bacterial infections.
We launched Stamlo, an amlodipine, in India, which continues to be no. 1 in the segment in the country.
To make our affordable medicines accessible not just in India but the world, we began to build an international presence and started our globalisation journey. We entered the US Generics market, establishing our offices in New Jersey.
The Dr. Reddy’s Foundation was established as an innovative experiment in poverty alleviation, targeted at economically and socially vulnerable children, youth and women.
We became the first Indian pharmaceutical to out-license an original/New Chemical Entity molecule.
We started our Biologics business to offer Indian consumers high–cost medicines at affordable prices.
Dr. Reddy’s Laboratories set up a ‘satellite’ research subsidiary in the US.
We became India’s third-largest pharmaceutical company.
Post the merger of our group companies, we listed our shares on the New York Stock Exchange, becoming the first pharmaceutical company from Asia, outside Japan, to do so. Continuing our global expansion, we also made our first overseas acquisitions – BMS Laboratories Limited and Meridian Healthcare in the UK.
We launched a drug for advanced prostate cancer in India, becoming the first company to introduce Bicalutamide in India. During this year, we also established the Dr. Reddy’s Foundation For Health Education, and set up a breast cancer helpline in Mumbai.
Dr. Reddy’s launched the first generic product under its label in the US.
We got access to drug delivery platforms in the dermatology segment through the acquisition of Trigenesis Therapeutics Inc., a US-based company.
Dr. Reddy’s launched India’s first drug for treatment of diabetic foot ulcers. We also became the only pharmaceutical company in India to win the prestigious WorldStar awards for anti-counterfeit and patient protection packaging.
Our revenues touched USD 1 billion.
Dr. Reddy’s became India’s top pharmaceutical company in turnover and profitability. During this year, we also launched the world’s first biosimilar monoclonal antibody to treat certain autoimmune diseases and cancers like non-Hodgkin’s lymphoma.
We made a series of important acquisitions in the US, UK and Italy.
We crossed USD 150 million in revenue in Russia and the CIS region.
We introduced Dose Counter Inhalers in India for the first time and launched the world’s first biosimilar darbepoetin alfa, which offers relief to anaemia patients.
Dr. Reddy’s announced the completion of the acquisition of US penicillin facility and products from GlaxoSmithKline.
We crossed USD 2 billion in revenue
We launched a slate of important products and won several awards for best managed board, HR excellence, corporate governance and investor relations.
Dr. Reddy’s Laboratories partnered with NICE Foundation to launch the Community Health Intervention Program(CHIP) in Andhra Pradesh. It is one of the company’s most dynamic and thriving community initiatives.
Our North America Generics business crossed the USD 1 billion mark, a significant shot in the arm. We also acquired a select portfolio of Belgium-based UCB’s established brands in India, Nepal, Sri Lanka and Maldives.
Dr. Reddy’s entered the branded consumer health arena through the acquisition of six OTC brands from Ducere Pharma. We also announced our entry into Colombia with a portfolio of high-quality and affordable medicines for cancer patients.
We expanded our commercial operations in Europe during this year as we introduced our portfolio of generics in France. This followed the launch of select products from our hospital portfolio in Italy and Spain.
Our subsidiary Aurigene Discovery Technologies set up a dedicated programme to develop oral immuno-oncology drugs. We also successfully launched a critical generic product to treat opioid addiction in the US.
We entered the nutrition segment in India with the launch of Celevida, a first-of-its-kind product in Dr. Reddy’s nutrition portfolio. We also created GLOWRIA, a 40-strong all-women medical representative team for our cosmetic and aesthetic division.
As the coronavirus pandemic spread across the world, we went into overdrive to keep our workforce safe and continue the supply of critical medicines. We entered significant partnerships with global innovator companies to bring a diverse range of Covid-19 therapeutics to India. These include deals with Fujifilm Toyama Chemical for Favipiravir, Gilead Sciences for Remdesivir and the Russian Direct Investment Fund for the Sputnik V vaccine.
We launched our first generic Otic suspension product in theUS.
We acquired select business divisions of Wockhardt in India,as well as certain anti-allergy brands from the Glenmark portfolio in Russia,Ukraine, Kazakhstan and Uzbekistan.
Additionally, we became the first Indian pharmaceuticalcompany to join the Science Based Targets initiative.
The pandemic continues to take its toll, with successive waves hitting countries across the world. In a bid to provide wider treatment options for patients, we have teamed up with Eli Lilly to bring Baricitinib to India.
We have partnered with Merck to make Molnupiravir accessibleto Covid-19 patients around the world. The drug is currently in Phase 3clinical trials.
In collaboration with India’s Defence Research and Development Organisation, we are producing 2-DG as an adjunct therapy to treat Covid-19.
Sputnik V was given Emergency Use Authorisation in India.
We signed an exclusive licensing agreement with China’s Shenzhen Pregene Biopharmato bring CAR-T therapy to India.
We made our entry into Portugal, The Netherlands, The Czech Republic and Slovakia with the launch of Azacitidine in these markets. The product is used to treat a rare type of cancer called Myelodysplastic Syndrome.
As the second wave ripped through India, we focused our relief efforts in three areas — enhancing hospital infrastructure such as step-down beds and ICU facilities; providing critical equipment and supplies to hospitals such as ventilators, oxygen plants and oxygen concentrators; and providing medicines for Covid-19.
